相似文献
1
Durable Complete Remission of PD-L1 Positive NUT Carcinoma Treated With Concurrent Chemotherapy and Radiation.
Perm J. 2020 Dec;25:1-3. doi: 10.7812/TPP/20.093.
2
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12.
3
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
J Clin Oncol. 2021 Feb 20;39(6):619-630. doi: 10.1200/JCO.20.01055. Epub 2021 Jan 13.
4
High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer.
Anticancer Res. 1999 Jan-Feb;19(1B):693-8.
5
Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report.
Ann Oncol. 2002 Mar;13(3):460-9. doi: 10.1093/annonc/mdf028.
6
Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma.
Cancer. 1996 Jun 15;77(12):2458-63. doi: 10.1002/(SICI)1097-0142(19960615)77:12<2458::AID-CNCR7>3.0.CO;2-I.
7
Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
Invest New Drugs. 2021 Feb;39(1):269-271. doi: 10.1007/s10637-020-00983-6. Epub 2020 Aug 11.
8
Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.
JAMA Oncol. 2017 Aug 1;3(8):1120-1129. doi: 10.1001/jamaoncol.2016.4280.
9
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.
Ann Oncol. 1997 Jan;8(1):57-64. doi: 10.1023/a:1008209713568.
10
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
Ann Oncol. 1997 Jan;8(1):49-56. doi: 10.1023/a:1008232329498.
引用本文的文献
1
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck.
Nat Rev Clin Oncol. 2025 Apr;22(4):292-306. doi: 10.1038/s41571-025-00986-3. Epub 2025 Feb 3.
2
Transcriptomic profiling of a late recurrent nuclear protein in testis carcinoma of the lung 14 years after the initial operation: a case report.
Transl Lung Cancer Res. 2024 Jul 30;13(7):1756-1762. doi: 10.21037/tlcr-24-259. Epub 2024 Jul 11.
3
Clinical and molecular features of pulmonary NUT carcinoma characterizes diverse responses to immunotherapy, with a pathologic complete response case.
J Cancer Res Clin Oncol. 2023 Aug;149(9):6361-6370. doi: 10.1007/s00432-023-04621-5. Epub 2023 Feb 8.
4
Case report: NUT carcinoma with MXI1::NUTM1 fusion characterized by abdominopelvic lesions and ovarian masses in a middle-aged female.
Front Oncol. 2023 Jan 11;12:1091877. doi: 10.3389/fonc.2022.1091877. eCollection 2022.
5
-Rearranged Neoplasms-A Heterogeneous Group of Primitive Tumors with Expanding Spectrum of Histology and Molecular Alterations-An Updated Review.
Curr Oncol. 2021 Nov 7;28(6):4485-4503. doi: 10.3390/curroncol28060381.
本文引用的文献
1
An Overview of Molecular Mechanism, Clinicopathological Factors, and Treatment in NUT Carcinoma.
Biomed Res Int. 2019 Nov 11;2019:1018439. doi: 10.1155/2019/1018439. eCollection 2019.
2
NUT midline carcinoma: Current concepts and future perspectives of a novel tumour entity.
Crit Rev Oncol Hematol. 2019 Dec;144:102826. doi: 10.1016/j.critrevonc.2019.102826. Epub 2019 Nov 1.
3
Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.
Oncologist. 2019 Aug;24(8):e740-e748. doi: 10.1634/theoncologist.2018-0477. Epub 2019 Jan 29.
4
NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment.
Pathol Int. 2018 Nov;68(11):583-595. doi: 10.1111/pin.12727. Epub 2018 Oct 26.
5
Patterns of care and impact of prognostic factors in the outcome of NUT midline carcinoma: a systematic review and individual patient data analysis of 119 cases.
Eur Arch Otorhinolaryngol. 2018 Mar;275(3):815-821. doi: 10.1007/s00405-018-4882-y. Epub 2018 Jan 22.
6
Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck.
Cancer. 2016 Dec 1;122(23):3632-3640. doi: 10.1002/cncr.30242. Epub 2016 Aug 10.
7
MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma.
Oncogene. 2014 Mar 27;33(13):1736-1742. doi: 10.1038/onc.2013.126. Epub 2013 Apr 22.
8
Clinicopathologic features and long-term outcomes of NUT midline carcinoma.
Clin Cancer Res. 2012 Oct 15;18(20):5773-9. doi: 10.1158/1078-0432.CCR-12-1153. Epub 2012 Aug 15.
Zotero 插件